UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission File Number) | (IRS Employer Identification No.) |
| of incorporation) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 4.01 | Changes in Registrant's Certifying Accountant |
The Audit Committee of the Board of Directors, or the Audit Committee, of Eagle Pharmaceuticals, Inc., or the Company, conducted a competitive request-for-proposal process to determine the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2020.
Following careful evaluation, on September 25, 2020, the Audit Committee approved the engagement of Ernst & Young, LLP, or E&Y, as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2020, and dismissed BDO USA, LLP, or BDO, the Company’s current independent registered public accounting firm.
(a) Dismissal of Independent Registered Public Accounting Firm
As discussed above, on September 25, 2020, the Audit Committee dismissed BDO as the Company’s independent registered public accounting firm.
BDO’s reports on the Company’s consolidated financial statements as of and for the fiscal years ended December 31, 2019 and 2018 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty or audit scope. BDO’s audit report for the fiscal year ended December 31, 2019 included an emphasis-of-matter paragraph stating that the Company adopted Accounting Standards Update 2016-02, Leases, on January 1, 2019, and BDO’s audit report for the fiscal year ended December 31, 2018 included an emphasis-of-matter paragraph stating that the Company adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers, on January 1, 2018.
In addition, BDO’s reports on the effectiveness of internal control over financial reporting as of December 31, 2019 and 2018 did not contain any adverse opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles.
During the fiscal years ended December 31, 2019 and 2018, and the subsequent interim period through September 25, 2020, there were
| (i) | no disagreements (as described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and BDO on any matter of accounting principles or practices, consolidated financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to BDO’s satisfaction, would have caused BDO to make reference thereto in their reports on the consolidated financial statements for such years, and |
| (ii) | no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K. |
The Company provided a copy of the foregoing disclosures to BDO and requested that BDO furnish a letter addressed to the Securities and Exchange Commission, pursuant to Item 304(a)(3) of Regulation S-K, stating whether or not BDO agrees with the above disclosures. A copy of BDO’s letter, dated October 1, 2020, is filed as Exhibit 16.1 to this Form 8-K.
(b) Appointment of New Independent Registered Public Accounting Firm
On September 25, 2020, the Audit Committee approved the engagement of E&Y as the Company’s independent registered public accounting firm, effective immediately, to perform independent audit services for the Company’s fiscal year ending December 31, 2020, subject to execution of an engagement letter between the Company and E&Y.
During the fiscal years ended December 31, 2019 and 2018, and the subsequent interim period through September 25, 2020, neither the Company nor anyone acting on its behalf has consulted with E&Y regarding:
| (i) | the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements or the effectiveness of internal control over financial reporting, and neither a written report or oral advice was provided to the Company that E&Y concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, |
| (ii) | any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K, or |
| (iii) | any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K. |
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. | Description | |
| 16.1 | Letter from BDO USA, LLP to the Securities and Exchange Commission, dated October 1, 2020. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: October 1, 2020 | EAGLE PHARMACEUTICALS, INC. | |
| By: | /s/ Scott Tarriff | |
| Scott Tarriff | ||
| Chief Executive Officer | ||
Exhibit 16.1
October 1, 2020
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on September 25, 2020, to be filed by our former client, Eagle Pharmaceuticals, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm.
Very truly yours,
/s/ BDO USA, LLP
Cover |
Sep. 25, 2020 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Sep. 25, 2020 |
| Entity File Number | 001-36306 |
| Entity Registrant Name | Eagle Pharmaceuticals, Inc. |
| Entity Central Index Key | 0000827871 |
| Entity Tax Identification Number | 20-8179278 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 50 Tice Boulevard |
| Entity Address, Address Line Two | Suite 315 |
| Entity Address, City or Town | Woodcliff Lake |
| Entity Address, State or Province | NJ |
| Entity Address, Postal Zip Code | 07677 |
| City Area Code | 201 |
| Local Phone Number | 326-5300 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock (par value $0.001 per share) |
| Trading Symbol | EGRX |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |